BioCryst Pharmaceuticals
BCRX
123 hedge funds and large institutions have $817M invested in BioCryst Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 40 reducing their positions, and 14 closing their positions.
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
45% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $1.44M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
7% more capital invested
Capital invested by funds: $764M → $817M (+$53M)
6% more funds holding
Funds holding: 116 → 123 (+7)
0.78% more ownership
Funds ownership: 91.56% → 92.34% (+0.78%)
23% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.18M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.38M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.72M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.92M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.66M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.66M |
| 4 |
Millennium Management
New York
|
-$2.89M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.77M |
BCRX Hedge Fund Activity: Q4 2018 in Review
123 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2018, worth a combined $817M — up 6.9% from $764M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new BCRX positions and 14 closed out — a net gain of 7 holders — while 31 added to existing stakes and 40 trimmed.
The largest buyer was RA Capital Management, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $5.92M.
- 123 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2018, up from 116 in Q3 2018.
- Funds reported $817M of BioCryst Pharmaceuticals stock for Q4 2018, up 6.9% quarter-over-quarter.
- 21 funds opened new BioCryst Pharmaceuticals positions in Q4 2018 and 14 closed out, a net change of +7 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2018 was RA Capital Management, an estimated $11.1M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2018 was Fidelity Investments, an estimated $5.92M sold.
Based on aggregated 13F filings for Q4 2018.